<DOC>
	<DOCNO>NCT00110162</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Androgen deprivation therapy may stop adrenal gland make androgen . PURPOSE : This randomized phase III trial study well androgen deprivation therapy work treat patient prostate cancer .</brief_summary>
	<brief_title>Androgen Deprivation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival ( acceptable morbidity ) patient prostate cancer treat delayed v immediate androgen deprivation therapy ( ADT ) . Secondary - Compare cancer-specific survival patient treat regimen . - Compare clinical progression patient treat regimen . - Compare time first androgen independence patient treat regimen . - Compare complication rate incidence timing ( e.g. , cord compression pathological failure ) patient treat regimen . - Compare treatment-related morbidity ( include cognitive morbidity osteoporosis ) patient treat regimen . - Compare quality life patient treat regimen . - Determine prognostic factor progression patient treat delayed ADT . OUTLINE : This multicenter , randomize , control study . Patients group 1 stratify accord prior therapy ( prostatectomy v radiotherapy v prostatectomy radiotherapy ) , relapse-free interval ( &lt; 2 year vs ≥ 2 year ) , type plan androgen deprivation therapy ( ADT ) ( continuous v intermittent ) , participate center . Patients group 2 stratify accord type plan ADT ( continuous v intermittent ) , disease type ( localize vs metastatic ) , participate center . Patients group randomize 1 2 treatment arm . - Arm I ( delay ADT ) : Beginning least 2 year study entry exhibit evidence significant disease progression* , patient receive either continuous ADT OR intermittent ADT comprise either bilateral orchiectomy OR luteinizing hormone-releasing hormone agonist without oral antiandrogen therapy . - Arm II ( immediate ADT ) : Beginning immediately randomization , patient receive either continuous ADT OR intermittent ADT arm I . NOTE : *Patients group 1 begin delay ADT least 2 year study entry unless 1 follow clinical criterion present : prostate-specific antigen ( PSA ) double time &lt; 12 month PSA ≥ 10 ng/mL OR PSA double time ≤ 6 month base 3 consecutive measurement obtain ≥ 2 month apart OR development metastasis symptom . Patients group 2 begin delay ADT least 2 year study entry unless 1 follow clinical criterion present : development symptom OR PSA ≥ 60 ng/mL OR PSA double time ≤ 6 month base 3 consecutive measurement obtain ≥ 2 month apart . After 9 month ADT , patient assess response . Patients PSA &lt; 4 ng/mL may discontinue ADT . These patient follow every 3 month . Treatment may restart PSA &gt; 20 ng/mL OR PSA &gt; PSA level study entry OR clinical progression . Quality life assess baseline , every 6 month 2 year , annually 3 year . Patients follow every 3 month 2 year , every 6 month 3 year , periodically thereafter discretion principal investigator . PROJECTED ACCRUAL : A total 300-2,000 patient accrue study within 2-5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Prostatespecific antigen ( PSA ) relapse OR incurable disease diagnose within past 2 month AND meet criterion either follow group : Group 1 In PSA relapse definitive radical treatment ( prostatectomy radiotherapy ) , evidence 1 following : Postprostatectomy PSA level ≥ 0.2 ng/mL At least 3 rise PSA level ( postradiotherapy ) obtain ≥ 1 month apart , last PSA obtain within past 2 month No metastatic disease bone scan abdominopelvic CT scan Group 2 Not suitable radical treatment primary diagnosis Not plan receive curative treatment Localized metastatic disease No symptomatic disease require radiotherapy immediate hormonal therapy No symptomatic disease require therapy PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy At least 5 year Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No significant comorbid condition would limit life expectancy &lt; 5 year PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy At least 12 month since prior androgen deprivation therapy ( ADT ) administer neoadjuvant concurrent ( radiotherapy ) setting ( group 1 ) No prior ADT ( group 2 ) Radiotherapy See Disease Characteristics See Endocrine therapy Surgery See Disease Characteristics Other No concurrent enrollment TROG96.01 TROGRADAR protocol</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>